A Review on Future Directions and Emerging Technologies in Cancer Gene Therapy

Although cancer remains one of the foremost causes of human death worldwide, the traditional therapies available in the field, of which chemotherapy, radiation, and surgery are but a few examples, usually manifest limited efficacy and high toxicity, while the development of resistance often renders them ineffective. One such hope in cancer therapy is the field of gene therapy targeted toward either switching off or correcting the genetic abnormality responsible for the advancement of cancer. In the past few decades, the field has experienced major advancements in gene-editing technologies, newer delivery systems, and immunogene therapy. This review provides detailed insight into current advances in cancer gene therapy and its future potentials while underlining freshly emerging technologies such as CRISPR-Cas gene editing, RNA-based medicine (siRNA, mRNA, and miRNA), and the second generation of CAR-T cell therapy. Non-viral gene delivery strategies, such as nanoparticles, liposomes, and extracellular vesicles, are put forward as safer and more effective solutions than viral vectors. Further, applications of AI and computational biology in gene therapy are described, emphasizing on improving gene-editing accuracy, prediction of therapeutic outcomes, and personalizing cancer treatment. Synthetic biology approaches such as engineered gene circuits and programmable gene switches are being targeted for their ability to increase therapeutic specificity and safety. However, even with these prospects, challenges including off-target effects, immunogenicity, scale-up, regulatory barriers, and various other ethical issues remain. This review thus reveals the fast pace that is characteristic for cancer gene therapy along with the opportunities and challenges ahead. This improves massively the future of cancer gene therapy when all present-day challenges are tackled with the help of cutting-edge technologies to better improve the outcome of patients with more accurate, long-lasting, and less invasive therapeutic interventions.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-04-04
DOI
https://doi.org/10.5281/zenodo.15150472
Primary Topic
CRISPR and Genetic Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Review on Future Directions and Emerging Technologies in Cancer Gene Therapy

Zenodo (CERN European Organization for Nuclear Research)
CRISPR and Genetic Engineering
article

A Review on Future Directions and Emerging Technologies in Cancer Gene Therapy

article en

Abstract

Although cancer remains one of the foremost causes of human death worldwide, the traditional therapies available in the field, of which chemotherapy, radiation, and surgery are but a few examples, usually manifest limited efficacy and high toxicity, while the development of resistance often renders them ineffective. One such hope in cancer therapy is the field of gene therapy targeted toward either switching off or correcting the genetic abnormality responsible for the advancement of cancer. In the past few decades, the field has experienced major advancements in gene-editing technologies, newer delivery systems, and immunogene therapy. This review provides detailed insight into current advances in cancer gene therapy and its future potentials while underlining freshly emerging technologies such as CRISPR-Cas gene editing, RNA-based medicine (siRNA, mRNA, and miRNA), and the second generation of CAR-T cell therapy. Non-viral gene delivery strategies, such as nanoparticles, liposomes, and extracellular vesicles, are put forward as safer and more effective solutions than viral vectors. Further, applications of AI and computational biology in gene therapy are described, emphasizing on improving gene-editing accuracy, prediction of therapeutic outcomes, and personalizing cancer treatment. Synthetic biology approaches such as engineered gene circuits and programmable gene switches are being targeted for their ability to increase therapeutic specificity and safety. However, even with these prospects, challenges including off-target effects, immunogenicity, scale-up, regulatory barriers, and various other ethical issues remain. This review thus reveals the fast pace that is characteristic for cancer gene therapy along with the opportunities and challenges ahead. This improves massively the future of cancer gene therapy when all present-day challenges are tackled with the help of cutting-edge technologies to better improve the outcome of patients with more accurate, long-lasting, and less invasive therapeutic interventions.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 52%
CRISPR and Genetic Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.